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A B S T R A C T
Purpose: To review the legislation for non-commercial driving licenses in the Western world for
unprovoked ﬁrst seizures (UFS) and recurrence of established epilepsy, and to examine available
evidence on the road trafﬁc accident (RTA) risk in people with seizures.
Methods: Regulations for non-commercial driving licenses were sought from appropriate national or
state authorities and epilepsy societies. The literature was searched for consensus guidelines and data
relevant to risk analysis, including an appropriate seizure-free period (SFP).
Results: The SFP varied widely from 3 to 24 months and in most countries no distinction was made
between UFS and recurrence of established epilepsy. In the European Union (EU), harmonisation is
underway but implementation of the relevant directive has been slow. The excess risk of RTA in epilepsy
is minimal, especially compared to other factors such as alcohol, and few accidents result from seizures
at the wheel. Risk analysis supports the shortened SFPs that are being enacted in the EU.
Conclusion: Regulations across the world continue to vary widely, and the available data support rules
which are less stringent than those currently in force in many parts of the Western world. The ongoing
European harmonisation is encouraging but much work remains to be done in revising legislation
elsewhere, and in strengthening the theoretical foundations underpinning driving regulations.
 2012 British Epilepsy Association. Published by Elsevier Ltd. 
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Driving is often considered an essential part of modern-day life.
Any restriction marks a signiﬁcant event impinging upon
independence, employment, socioeconomic status and quality of
life.1,2 In people with epilepsy (PWE), the inability to drive is a
fundamental concern and a common reason to consider surgery2–4
with the ability to drive after successful surgery a major
contributor to employability.5
An individual does not automatically possess a right to drive as
permission is either granted or denied by the country or state, and
driving regulations for PWE have existed for around a century. In
the past lifetime bans were common, but mounting recognition of
the socioeconomic necessity of driving and a growing, generally
favourable safety record have led to increasing liberalisation.6 In§ All information is presented for academic purposes only. The authors assume no
responsibility for any errors or omissions. Medical practitioners should always refer
to the latest relevant guidelines and legislation.
Abbreviations: AED, anti-epileptic drugs; CI, conﬁdence interval; EU, European
Union; PWE, people with epilepsy; RR, relative risk; RTA, road trafﬁc accidents; SFP,
seizure-free period; UFS, unprovoked ﬁrst seizure.
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Open access unthe UK, for example, the lifetime ban introduced in the 1920s was
reduced to 3 years in 1969, 2 years in 1982, 1 year in 1993 and
more recently to 6 months in the case of unprovoked ﬁrst seizures
(UFS).7,8
Seizures are a common clinical problem, thus underscoring the
importance of relevant driving regulations. Epilepsy has a
prevalence of approximately 1%9 and its onset often predates
beginning to drive or work. The lifetime incidence of UFS is even
higher at 1 in 20.10 Driving regulations aim to maximise public
safety whilst preserving individual freedom as much as possible.11
The action of revoking a licence is primarily taken to protect
passengers and other road users, rather than to safeguard the
driver.12 Excessive restriction carries the risk of non-compliance13
or under-reporting of seizures by patients.14
Driving legislation for seizures was previously reviewed in the
USA in 199415 and 200116 and internationally in 1992,17 199418
and 2000.19 These studies did not distinguish between UFS and
established epilepsy, and noted a signiﬁcant variability between
states and countries both in the duration of the seizure-free period
(SFP) required (3–36 months) and in any exceptions for speciﬁc
types of seizures, for example exclusively sleep-related events.
Signiﬁcant additional evidence has become available in the
decade since the last review and this has led to a recent European
Union (EU) directive. Here we review the legislation for group 1der CC BY-NC-ND license. 
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and recurrence of established epilepsy. We present the European
situation prior to the introduction of the EU directive to highlight
the heterogeneity before harmonisation.
2. Methods
Regulations for non-commercial driving licenses were sought
from driver licensing authorities and epilepsy societies in Canada,
Western Europe, Australia and New Zealand. For the USA, data
were retrieved from state legislature and the state divisions or
departments of motor vehicles. The sources were reviewed for the
SFP required after UFS or after recurrence of known epilepsy, and
for any requirement for physicians to provide statutory reports of
patients with seizures. For Western European countries, the
regulations prior to the implementation of EU Commission
Directive 2009/112/EEC were used as the basis of the review
whilst for all other countries the data is presented as at August
2011.
Pubmed and Scopus were searched using the terms ‘‘epilepsy’’
or ‘‘seizure’’ in combination with ‘‘driv*’’, ‘‘recurrence’’ or
‘‘prognosis’’. Relevant papers written in English were retrieved,
and their reference lists were hand-searched for further relevant
literature. Available consensus guidelines were also obtained.
3. Results
Most US states required a SFP of 3, 6 or 12 months whilst others
employed case-by-case decisions (Fig. 1). Legislation did not
distinguish UFS and established epilepsy. Canadian provinces and
territories mostly followed the guidelines of the Canadian Council
of Motor Transport Administrators,20 which stipulated a 6-month
SFP, but with no restriction applying in the case of an UFS with
normal neurological assessment and EEG. Quebec had separate
rules specifying a 12-month SFP; again no restriction applied after
an UFS with normal assessment and EEG. Statutory physician
reporting was required in 6 US states (California, Delaware,
Nevada, New Jersey, Oregon, Pennsylvania), and 7 Canadian
provinces and territories (Manitoba, New Brunswick, Newfound-
land & Labrador, Northwest Territories, Ontario, Prince Edward
Island, Yukon).
In Western Europe, similar variability in the SFP was observed.
However, regulations were generally more stringent than in North
America, requiring a SFP of up to 24 months. Several countries
distinguished UFS and recurrence of established epilepsy with
more restrictive regulations for the latter, except in Denmark
where UFS were associated with a longer SFP. The only country in
which we found evidence of mandatory physician reporting was
Norway.21
New Zealand required a 12-month SFP for UFS or recurrence of
established epilepsy, which could be reduced to 6 months on the
recommendation of a neurologist. In Australia, the SFP ranged from
6 months for an UFS or successful treatment of newly diagnosed
epilepsy to 24 months for uncontrolled epilepsy. Shorter periods of
1 and 3 months respectively were permitted after a provoked and
unprovoked recurrence of previously controlled epilepsy. Australia
and New Zealand did not require mandatory reporting.
This summary only touches on the complex nature of legislation
surrounding driving and PWE. In many Western countries,
requirements could be lessened on the recommendation of a
neurologist and numerous exceptions to the regulations existed.
Common themes included acute symptomatic seizures, seizures
triggered by planned medication changes, seizures occurring
exclusively from sleep and seizures associated with a prolonged
aura. Due to their wide variety these are not reviewed further here
but reference should be made to the original regulations.4. Discussion
Western driving regulations for UFS and recurrence of
established epilepsy remain very heterogeneous. To provide an
informed context for suggesting possible improvements, we
review the risks posed by people with seizures who drive, as well
as previous consensus statements and apparent limitations of
driving rules.
4.1. Risk of accidents
Seizure-related road trafﬁc accidents (RTAs) are often sensa-
tionalised in the press which may result in an exaggerated public
risk perception. Therefore, fundamental questions include the
proportion of RTAs in PWE that are attributable to seizures, the
magnitude of the increased risk of RTAs in PWE, and a comparison
of this increased risk to other medical conditions or factors such as
age and sex.
Although approximately half of seizures at the wheel lead to an
RTA,1 only a minority of accidents in PWE are due to seizures
(11%)22 or side effects of medication.23 The majority are due to
driver error, the same major cause as in the general population.22 A
meta-analysis of eight studies found a relative risk (RR) of RTAs in
PWE of 1.84 (95% conﬁdence interval (CI) 1.68–2.02).24 Amongst
PWE, the greatest risk of RTAs is posed by those who are young,
male or unmarried; have a history of multiple, complex partial or
generalised seizures; are not taking AEDs or have comorbidities
such as alcohol or drug abuse and psychiatric disorders.25,26 By
contrast, a longer SFP, reliable auras, fewer prior non-seizure
related accidents and more physician-directed medication changes
– presumably indicative of active management – all decrease
accident risk.27
In comparison to other factors, epilepsy contributes little to
increased risk of RTAs. The largest retrospective cohort study
undertaken in over 30,000 US subjects reported an RR of 1.33
(1.00–1.73), which was comparable to the RR in people with
diabetes28 or medical conditions which do not carry driving
restrictions, such as cardiovascular disease. The highest accident
rates are seen in people without epilepsy who are young, elderly or
under the inﬂuence of alcohol or drugs. The RR in PWE is far less
than the ﬁvefold increase in RTA risk seen in healthy drivers under
the age of 25,29 and the accident risk of women with epilepsy is less
than that of men without epilepsy.30 A case-control study of RTAs
did not show any overrepresentation of PWE in the accident
group,31 and the lifetime risk of RTAs does not differ between those
with and without epilepsy.32 As PWE drive fewer miles than the
general population, this may limit any increase in accidents and
some US states use this as a basis to issue time- or distance-limited
driving licences to PWE.
The minimal increase in RTA risk in comparison to other risk
factors is reﬂected in the low proportion of accidents related to
seizures: between 0.02% and 0.25% of accidents are seizure-
related17,33–35 whilst 31% of accidents are related to alcohol.35 Out
of all medically related crashes, between 4.2% (35) and 30% (34) are
caused by seizures. Sonnen estimated that, on average, a driver
would be involved in an RTA with somebody having a seizure once
every 4000 years.36 Fewer accidents occur due to epilepsy than
through natural death at the wheel.22
4.2. Risk of recurrence
Seizures typically cause sudden, episodic and unpredictable
incapacity rather than continuous impairment.12 Hence, physical
assessment is informative in patients with either ﬁxed (e.g. stroke)
or progressive impairment (e.g. dementia), but not in PWE where
ﬁtness to drive is judged using estimates of the risk of recurrence.
Fig. 1. (A–C) Typical seizure-free periods (SFPs) required after an unprovoked ﬁrst seizure (UFS) or recurrence of established epilepsy. For many countries/states the SFPs were
identical in both cases (uniform shading). In several countries, the SFP was longer for recurrence of epilepsy than for UFS; the opposite situation applied in Denmark and
Australia (striped shading indicating both SFPs). Several US states use case-by-case decisions rather than ﬁxed SFPs (black shading). Underlined countries/states required
statutory physician reporting.
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many observational studies and several randomised trials. 40–50%
of untreated patients suffer a recurrence within 2 years of the
index event, with the risk being highest immediately after the
event before dropping off over time.37 The proportion of
recurrences that occur within a given time of the ﬁrst seizurevaries between studies, mostly because of differences in study
populations and in the duration of follow-up.
Most studies are ill-suited to informing an appropriate period of
driving restriction after an UFS for two reasons. First, study
populations often included patients who were below driving age,
suffered provoked seizures or had multiple seizures before
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was treated with anti-epileptic drugs (AEDs), which reduce
recurrence risk by around half.37 Results were usually reported
in a format which does not allow these groups to be excluded.
Secondly, studies typically reported recurrence risk at given time
points after the index event. However, what is required to inform
driving regulations is recurrence risk within a certain interval (e.g.
12 months) after a given SFP. Such risk estimates can then be
compared to a risk threshold deemed acceptable by the policy
maker.Only two studies have reported recurrence risk in this
manner,38,39 and only Bonnett et al.38 speciﬁcally addressed
recurrence risk after a single UFS in untreated patients of driving
age, using a reanalysis of the Multi-Centre Study of Early Epilepsy
and Single Seizure (MESS) trial data.40 Recurrence risk was
estimated in the 12 months following a SFP of 6, 12, 18 or 24
months after the index event. After a SFP of 6 months, the 12-
month recurrence risk was 18% and thus below the maximum
acceptable risk of 20–40% stipulated by the EU,13 prompting a post-
UFS driving ban of 6 months to be speciﬁed in the EU directive.41 In
line with previous studies, recurrence risk decreased with
increasing SFP.
However, several points must be borne in mind. First, the
recurrence risk estimate of 18% from Bonnett et al.38 is a point
estimate whose 95% CI (13–23%) extends beyond the risk threshold
of 20% used in countries such as the UK.42 The use of interval
estimates has not been explicitly considered by public bodies, and
if such estimates were used, a decision whether to apply
conservative or liberal intervals would need to be made. Secondly,
these ﬁgures were calculated using unstratiﬁed data. Untreated
subgroups with risk factors (remote symptomatic aetiology,
abnormal EEG, abnormal CT/MRI) had estimated recurrence risks
of up to 32% (29–34%, 95% CI), highlighting that aggregate
population estimates may not necessarily prove a good ﬁt for a
given individual. Thirdly, only patients in whom there was
equipoise between immediate and delayed treatment were
recruited to MESS, so those with very low or very high recurrence
risk would not have been included. Hence, whilst the nature of the
risk factors is backed up by many previous reports (reviewed in
37,43,44), the numerical ﬁgures of Bonnett et al.38 should ideally be
corroborated in an observational study. Finally, recruitment to the
MESS study was often delayed by several weeks after the ﬁrst
event. Therefore, the dataset cannot illuminate the recurrence risk
early in the natural history, providing no reassurance for countries
that impose no driving restrictions after an UFS.
Considering the above data on the risk of accidents and the risk
of recurrence, it is little surprise that a reduction in the SFP from 12
to 3 months in Arizona was not associated with any signiﬁcant
increase in seizure-related accidents or fatalities,34 and that there
is no difference in accident rates between US states requiring a long
(6–12 months) or short (3 months) SFP.35 The ﬁndings in Arizona
should generalise as the RTA fatality rate (20.9 per 100,000
population per year) is comparable to other states of the USA
(range 6.4–37.9)45 and to European countries (range 2.5–22.4
across 25 countries).46 A literature review suggested that for an
UFS, the difference between a 3- and 6-month ban would be 0.7
serious accidents and 0.1 life per million population.13
4.3. Risk analysis
Risk analysis involves several factors other than recurrence risk:
the amount of time spent on the road, the probability and rate of
onset of incapacity, the probability of incapacity leading to an RTA,
and the likely outcome of an RTA. Numerical data on these factors
are scarce and risk analyses therefore heavily rely on assumptions.
For example, given a 20% probability of seizure in the next year for
a group 1 driver, 3% time spent on the road and one fatality fromevery 10 RTAs, the increase in annual fatalities in the UK would be
20, but this ﬁgure would vary between 5 and 70 if more optimistic
or pessimistic assumptions were used.12 The process of risk
analysis provides some reassurance that decisions are not made
arbitrarily but its inherent limitations must be appreciated.
Nevertheless this approach was adopted for the recent EU
directive.
Individualised risk models would ultimately be desirable, yet
they are unlikely to be forthcoming in the near future and may not
prove affordable.8 Special exceptions for patients with seizures
occurring only from sleep or with consistent and reliable auras
reﬂect a ﬁrst, pragmatic step in this direction,47 but – at least in the
case of purely sleep-related epilepsy – the evidence base for
current exceptions remains uncomfortably thin.48 Licensing
conditions other than a ban from driving can be imposed in some
countries, for example Australia, and include restricting the
number of passengers or prohibiting motorway driving.49
4.4. Consensus statements
Several consensus statements have been published. Following a
meeting in 1991, the American Academy of Neurology, Epilepsy
Foundation of America and American Epilepsy Society jointly
proposed a SFP of only 3 months with no distinction between UFS
and recurrent seizures in PWE.50 This interval could be altered by
both favourable and unfavourable modiﬁers, for example seizures
with a consistent and prolonged aura or those provoked by change
in medication or acute illness. Mandatory reporting was opposed.
These suggestions appear to have had little impact. In Canada, a
symposium in 1998 concluded that ‘‘a 6–12-month SFP was
appropriate’’ and that ‘‘mandatory reporting should be abol-
ished’’.51 Most Canadian provinces and territories have since
adopted more relaxed standards but many continue to require
mandatory reporting. Both North American statements are
however now quite dated.
European workshops were arranged by the International
League Against Epilepsy (ILAE) in 199552 and the International
Bureau for Epilepsy (IBE) in 1996.36 Their recommendations based
on deﬁned SFPs were not implemented. In 2000, the European
Council initiated a review of medical standards for drivers. The risk
assessment considered the risk to the patient rather the population
and used estimates of the percentage of seizures occurring during
the day (50%), time spent at the wheel (60 min a day, based on the
whole population rather than in PWE who may drive less), the
proportion of seizures leading to an accident (60%) and the
outcome of accidents. An annual seizure risk of 20–40% was
deemed acceptable; this corresponds to a relative accident risk of
3, equivalent to that of a driver aged over 75 years as compared to a
45–54-year-old driver. The review recommended SFPs of 6 and 12
months for UFS and recurrence of established epilepsy, respec-
tively, along with exceptions for seizures which were simple
partial, provoked or occurring solely from sleep. A Commission
Directive enacted these standards in 2009,41 aiming to foster
harmonisation whilst allowing individual states to be more
restrictive. Although it was to be implemented within 1 year in
all EU countries, uptake has been slow and remains partial.
4.5. Mandatory reporting
Mandatory reporting still exists in parts of the USA, Canada and
Western Europe. This is despite opposition in the above position
statements50,51,53,54 and by the ILAE and IBE.18 The ethical
arguments have been rehearsed extensively elsewhere.55,56 In
brief, the rationale for reporting is to reduce the risk to the patient
and the population. However, a comparison of two provinces
in Canada with different legislation showed that mandatory
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with the doctor–patient relationship, causing breach of conﬁ-
dentiality and decreased reporting of seizures by the patient to the
physician. The failure to report seizures may compromise care57
and mandatory reporting leads to fewer patients being counselled
regarding driving restrictions.58 It also makes physicians poten-
tially liable for failing to report patients who continue to drive
despite ongoing seizures.
4.6. Further limitations of driving regulations
The effectiveness of driving restrictions is also constrained by
seizure recognition, patient compliance and physician care.
Recognition of seizures by patients is limited. Approximately half
the events detected on video telemetry during surgery workup
remain unreported by the patient.59,60 The proportion of unre-
ported events is particularly high for complex partial (73%) or
nocturnal seizures (86%).60
Compliance with driving regulations amongst PWE has been
reported to vary from 14 to 57% in Canada, Belgium, the
Netherlands and New Zealand.13,61–63 In a Belfast study of 104
consecutive PWE, only 34 were able to state the law correctly, 3 of
75 patients who were ineligible to drive did so regardless, and 8
patients had driven illegally at some point.64 In a UK cohort of PWE,
of whom 11% had had an RTA in the prior year, only 27% complied
with the physician’s verbal and written advice to report to the
driving authority.65
Physician knowledge and counselling are further limiting
factors. A survey amongst doctors of all grades in Belfast found
that only 18% knew the correct driving regulations for PWE,66 and a
US study demonstrated that only one-third to one-half of PWE
recalled being counselled about the risks of driving.58 Finally,
fewer than half of all epileptic seizures occur in the context of
established epilepsy10 and 15% of seizure-related RTAs are due to a
ﬁrst seizure52 thus restricting the effectiveness of any legislation.
5. Conclusion
Driving is a key concern for patients with seizures. Appropriate
legislation should enable this without an undue increase in RTA
risk, thereby balancing maximisation of safety and minimisation of
any social and ﬁnancial detriments to individuals and society.
Historically, seizures often entailed total bans from driving, but
restrictions have become less stringent as evidence of the low
accident risk has accumulated. Indeed, the increase in accident risk
seen in PWE is minimal. Its magnitude is comparable to that seen
in other medical conditions such as diabetes, lower than that seen
in young drivers and insigniﬁcant when compared to drink-
driving. Recurrence risk is highest in the immediate period after a
seizure, and there is now sound data quantifying this risk after an
UFS. However, many other variable entering a risk analysis are less
well-deﬁned, and results must therefore be interpreted with
caution.
Western driving regulations for patients with seizures remain
highly variable with SFPs ranging from 3 to 24 months. European
legislation based on risk analysis has mandated the introduction of
a 6-month SFP for an UFS and 12 months for recurrence of
established epilepsy. Uptake has been slow, and legislation
remains discrepant in the rest of the world. There is particularly
variability in the USA reﬂecting greater independence of states and
a lack of an overarching drive for standardisation.
There remains considerable room for improving Western
driving regulations for patients with seizures. The data suggest
that in the absence of adverse risk factors a reduction of the SFP to 3
months is unlikely to lead to an unacceptable increase in accidents.
Observational studies to date are limited in scope and collaborativesharing of routine data between national driving authorities, motor
insurance companies and police would yield high quality data to
inform future risk models and legislation. Whilst our review
speciﬁcally addresses Western countries, other countries should
adopt a similar approach. It must be appreciated that driving is
intrinsically risky, and excess risk can only be minimised but not
eliminated, and it is likely that deﬁciencies in the recognition of
events, in counselling and in compliance will remain.
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